Literature DB >> 25638913

Primary malignant brain tumours, psychosocial distress and the intimate partner experience: what do we know?

Brenda Sabo.   

Abstract

From the time of diagnosis of a primary malignant brain tumour (PMBT) and throughout the illness trajectory, the patient and intimate partner face many psychosocial challenges ranging from fear and uncertainty to hope and loss (Fox & Lantz, 1998; Janda et al., 2007; Kvale, Murthy, Taylor, Lee, & Nabors, 2009). While many patients diagnosed with cancer may go on to live with cancer as a chronic illness, this may not be said of individuals diagnosed with a PMBT, in particular those diagnosed with a glioma, the most common form of brain tumour (Gupta & Sarin, 2002). Gliomas are associated with a short disease trajectory and multiple deficits (functional, cognitive and psychiatric). What makes the PMBT experience unique from other cancers is that the intimate partner must not only deal with the diagnosis of cancer in their spouse, but also the accompanying personality, functional and behavioural changes wrought by the disease, as well as grieve the loss of the person they once knew (Sherwood et al., 2004). These multi-dimensional deficits are thought to place the intimate partner, as caregiver, at greater risk for adverse psychosocial effects such as anxiety, depression and post traumatic stress (Goebel, von Harscher, & Mehdorn, 2011; Keir, Farland, Lipp, & Friedman, 2009). The following discussion will provide an overview of the extant literature on the experience of living with a PMBT from the intimate partner (spouse) perspective with a particular emphasis on how intimate partners cope. The intimate partner is considered to be the heterosexual or same-sex, married or common-law partner of the patient. Highlights from the psychotherapy practice of the author will be used to further strengthen the need for more research, education and enhanced practice to more effectively meet the unique needs of this under-researched and supported population.

Entities:  

Mesh:

Year:  2014        PMID: 25638913

Source DB:  PubMed          Journal:  Can J Neurosci Nurs        ISSN: 1913-7176


  6 in total

1.  PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.

Authors:  Lei Shi; Xifeng Fei; Zhimin Wang; Yongping You
Journal:  In Vitro Cell Dev Biol Anim       Date:  2015-07-14       Impact factor: 2.416

2.  Prevalence and Trends in the Neuropsychological Burden of Patients having Intracranial Tumors with Respect to Neurosurgical Intervention.

Authors:  Manju Dhandapani; Sandhya Gupta; Manju Mohanty; Sunil Kumar Gupta; Sivashanmugam Dhandapani
Journal:  Ann Neurosci       Date:  2017-05-12

3.  Curcumin potentiates the potent antitumor activity of ACNU against glioblastoma by suppressing the PI3K/AKT and NF-κB/COX-2 signaling pathways.

Authors:  Jun Zhao; Jiabin Zhu; Xiaoshu Lv; Jinshan Xing; Shuang Liu; Chen Chen; Yinghui Xu
Journal:  Onco Targets Ther       Date:  2017-11-15       Impact factor: 4.147

4.  Isoalantolactone inhibits IKKβ kinase activity to interrupt the NF-κB/COX-2-mediated signaling cascade and induces apoptosis regulated by the mitochondrial translocation of cofilin in glioblastoma.

Authors:  Jin-Shan Xing; Xun Wang; Yu-Long Lan; Jia-Cheng Lou; Binbin Ma; Tingzhun Zhu; Hongqiang Zhang; Dongsheng Wang; Zhikuan Yu; Zhongbo Yuan; Xin-Yu Li; Bo Zhang
Journal:  Cancer Med       Date:  2019-02-10       Impact factor: 4.452

Review 5.  Screening for Psychological Distress in Adult Primary Brain Tumor Patients and Caregivers: Considerations for Cancer Care Coordination.

Authors:  Wafa Trad; Eng-Siew Koh; Maysaa Daher; Alanah Bailey; Marina Kastelan; Dianne Legge; Marcia Fleet; Grahame K Simpson; Elizabeth Hovey
Journal:  Front Oncol       Date:  2015-09-22       Impact factor: 6.244

6.  Study on the Inhibitory Effect of Curcumin on GBM and Its Potential Mechanism.

Authors:  Xiaotao Su; Shaohua Chen; Hongyu Lu; Haoyu Li; Chao Qin
Journal:  Drug Des Devel Ther       Date:  2021-06-28       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.